

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

MILLENNIUM PHARMACEUTICALS, INC.,	)	
	)	
	)	
Plaintiff,	)	
	)	
v.	)	C.A. No. _____
	)	
TEVA PHARMACEUTICALS USA, INC., and TEVA PHARMACEUTICAL INDUSTRIES LTD.,	)	
	)	
	)	
Defendants.	)	

**COMPLAINT**

Plaintiff Millennium Pharmaceuticals, Inc., by its attorneys, alleges as follows:

**NATURE OF THE ACTION**

1. This is an action for patent infringement under the patent laws of the United States, Title 35, United States Code, that arises out of the filing by Defendant Teva Pharmaceuticals USA, Inc. (“Teva USA”) of Abbreviated New Drug Application (“ANDA”) No. 205857 with the U.S. Food and Drug Administration (“FDA”) seeking approval to manufacture and sell a generic version of VELCADE® prior to the expiration of U.S. Patent Nos. 6,713,446 and 6,958,319.

**PARTIES**

2. Plaintiff Millennium Pharmaceuticals, Inc. (“Millennium”) is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business at 40 Landsdowne Street, Cambridge, Massachusetts 02139. Millennium is engaged in the business of developing, manufacturing, and selling pharmaceutical drug products, particularly for use in the therapeutic area of oncology.

3. Upon information and belief, Defendant Teva Pharmaceutical Industries, Ltd. (“Teva Industries”) is a corporation organized under the laws of Israel, with its principal place of business at 5 Basel Street, Petach Tikva 49131, Israel. Upon information and belief, Teva Industries, itself and through its wholly-owned subsidiary and agent, Teva USA, manufactures, distributes and/or imports generic drugs for sale and use throughout the United States, including in this judicial district.

4. Upon information and belief, Defendant Teva USA is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business at 1090 Horsham Road, North Wales, Pennsylvania 19454. Upon information and belief, Teva USA is a wholly-owned subsidiary of Teva Industries and is controlled and/or dominated by Teva Industries. Upon information and belief, Teva USA manufactures and/or distributes generic drugs for sale and use throughout the United States and in this judicial district at the direction, under the control, and for the direct benefit of Teva Industries.

5. Upon information and belief, Teva Industries established Teva USA, its wholly-owned subsidiary, for the purposes of distributing, marketing, offering for sale and selling its generic drug products throughout the United States.

6. Upon information and belief, Teva USA and Teva Industries (collectively “Teva”) acted collaboratively in the preparation and submission of ANDA No. 205857. Upon information and belief, Teva USA’s preparation and submission of ANDA No. 205857 was done at the direction, under the control, and for the direct benefit of Teva Industries.

7. Upon information and belief, following any FDA approval of ANDA No. 205857, Teva Industries itself and through its wholly-owned subsidiary, Teva USA, will make, use, offer to sell, and/or sell the generic products that are the subject of ANDA No. 205857

throughout the United States, including in the State of Delaware, and/or import such generic products into the United States.

**JURISDICTION AND VENUE**

8. This action arises under the patent laws of the United States of America and this Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

9. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400(b).

10. The court has personal jurisdiction over each of the Defendants because, among other things, they have each committed, or aided, abetted, contributed to and/or participated in the commission of, a tortious act of patent infringement that has led to foreseeable harm and injury to Millennium, a Delaware corporation, which manufactures VELCADE® for sale and use throughout the United States, including the State of Delaware. This Court also has personal jurisdiction over the Defendants by virtue of, among other things, their systematic and continuous contacts with Delaware as set forth below, and for other reasons that will be presented to the Court if jurisdiction is challenged.

11. Upon information and belief, Teva USA currently manufactures and distributes for sale hundreds of drug products throughout the United States, including in this judicial district. Upon information and belief, Teva USA maintains a website, [www.tevagenetics.com](http://www.tevagenetics.com), listing the drug products it manufactures, markets, and/or sells in the United States. On its website, Teva USA represents that it “the largest generic pharmaceutical company in the country” and that “Teva Pharmaceuticals USA is a wholly owned subsidiary of Israeli-based Teva Pharmaceutical Industries, Ltd.”

12. Upon information and belief, Teva Industries directs the operations, management and activities of Teva USA in the United States.

13. Upon information and belief, Teva USA and Teva Industries collaborate in the manufacture, marketing, and sale of many pharmaceutical products (including generic drug products manufactured and sold pursuant to approved ANDAs) throughout the United States, including in this judicial district.

14. Upon information and belief, Teva USA sells generic drug products in the United States, including in this judicial district, that are manufactured by Teva Industries.

15. Teva Industries has taken advantage of the jurisdiction of this Court by affirmatively filing claims and counterclaims in other actions pending before this Court, including *Teva Pharmaceutical Industries, Ltd. & Teva Pharmaceuticals USA, Inc. v. Torrent Pharmaceuticals Ltd. & Torrent Pharma Inc.*, No. 07-24-JJF (D. Del.); *Takeda Pharmaceutical Company Ltd., Tap Pharmaceutical Products Inc., & Ethypharm, S.A. v. Teva Pharmaceuticals USA, Inc. & Teva Pharmaceutical Industries, Ltd.*, No. 07-331-SLR (D. Del); and *The Brigham & Women's Hospital, Inc., NPS Pharmaceuticals, Inc., & Amgen Inc. v. Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries, Ltd., & Barr Laboratories, Inc.*, No. 08-464-HB (D. Del.).

16. This Court has personal jurisdiction over Teva USA by virtue of, among other things, its systematic and continuous contacts with Delaware.

17. This Court has personal jurisdiction over Teva USA because, among other things, it is organized and exists under the laws of the State of Delaware.

18. This Court has personal jurisdiction over Teva Industries by virtue of, among other things, its systematic and continuous contacts with Delaware.

## BACKGROUND

19. United States Patent No. 6,713,446 (“the ’446 patent”), entitled “Formulation of Boronic Acid Compounds” (Exhibit A hereto), was duly and legally issued on March 30, 2004. The ’446 patent, which is owned by the United States of America as Represented by the Secretary of Health and Human Services, will expire on January 25, 2022.

20. United States Patent No. 6,958,319 (“the ’319 patent”), entitled “Formulation of Boronic Acid Compounds” (Exhibit B hereto), was duly and legally issued on October 25, 2005. The ’319 patent, which is owned by the United States of America as Represented by the Secretary of Health and Human Services, will expire on January 25, 2022.

21. Millennium has had an exclusive license to the ’446 and ’319 patents since December 2, 2002, by virtue of an exclusive worldwide license agreement for the research, development, and manufacture of MLN341 (bortezomib) for distribution, sale and use in oncology disease states. Pursuant to this license, Millennium has the right to bring suit in its own name, at its own expense, and on its own behalf for infringement of the ’446 and ’319 patents.

22. VELCADE® (bortezomib) is a proteasome inhibitor, for intravenous or subcutaneous administration, approved by the FDA for the treatment of patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior therapy.

23. Millennium sells VELCADE® in the United States pursuant to New Drug Application No. 21-602 which was approved by the FDA in 2003 and pursuant to several subsequent supplemental new drug applications for additional indications and a new route of administration which have also been approved by the FDA.

24. VELCADE®, or its use, is covered by one or more claims of the '446 and '319 patents, which have been listed in connection with VELCADE® in the FDA's publication, *Approved Drug Products with Therapeutic Equivalence Evaluations*, referred to as the "Orange Book."

25. By letter dated January 2, 2014, and received January 3, 2014 (the "Notice Letter"), Teva notified Millennium that it had submitted to the FDA ANDA No. 205857 for Bortezomib for Injection, 3.5 mg/vial, a generic version of VELCADE® ("the Teva ANDA Product").

26. In the Notice Letter, Teva stated that its ANDA included certifications pursuant to 21 U.S.C. § 355(j)(2)(B)(iv)(II) with respect to the '446 and '319 patents and alleged that the '446 and '319 patents are invalid, unenforceable, or will not be infringed by the commercial manufacture, use, offer for sale, or sale of the Teva ANDA Product.

27. This action is being commenced before the expiration of forty-five days from the date of Millennium's receipt of the Notice Letter.

**COUNT I**  
**INFRINGEMENT OF U.S. PATENT NO. 6,713,446**

28. Millennium incorporates each of the preceding paragraphs 1 – 27 as if fully set forth herein.

29. Teva's submission of ANDA No. 205857 for the purpose of obtaining approval to engage in the commercial manufacture, use, offer for sale, and/or sale of the Teva ANDA Product before the expiration of the '446 patent is an act of infringement of the '446 patent.

30. The commercial manufacture, use, offer for sale, sale and/or importation of the Teva ANDA Product would infringe one or more claims of the '446 patent.

31. Teva had knowledge of the '446 patent when it submitted its ANDA to the FDA.

32. Upon information and belief, use of the Teva ANDA Product in accordance with and as directed by Teva's proposed labeling for that product would infringe one or more claims of the '446 patent.

33. Upon information and belief, Teva intends to engage in the manufacture, use, offer for sale, sale, and/or importation of the Teva ANDA Product with its proposed labeling immediately and imminently upon approval of ANDA No. 205857.

34. Upon information and belief, Teva will actively induce infringement of the '446 patent when ANDA No. 205857 is approved, and plans and intends to, and will do so immediately and imminently upon approval.

35. Upon information and belief, Teva acted without a reasonable basis for believing that it would not be liable for infringing the '446 patent and/or actively inducing infringement of the '446 patent.

36. Unless Teva is enjoined from infringing the '446 patent and/or actively inducing infringement of the '446 patent, Millennium will suffer irreparable injury. Millennium has no adequate remedy at law.

**COUNT II**  
**INFRINGEMENT OF U.S. PATENT NO. 6,958,319**

37. Millennium incorporates each of the preceding paragraphs 1 – 36 as if fully set forth herein.

38. Teva's submission of ANDA No. 205857 for the purpose of obtaining approval to engage in the commercial manufacture, use, offer for sale, and/or sale of the Teva ANDA Product before the expiration of the '319 patent is an act of infringement of the '319 patent.

39. The commercial manufacture, use, offer for sale, sale and/or importation of the Teva ANDA Product would infringe one or more claims of the '319 patent.

40. Teva had knowledge of the '319 patent when it submitted its ANDA to the FDA.

41. Upon information and belief, use of the Teva ANDA Product in accordance with and as directed by Teva's proposed labeling for that product would infringe one or more claims of the '319 patent.

42. Upon information and belief, Teva intends to engage in the manufacture, use, offer for sale, sale, and/or importation of the Teva ANDA Product with its proposed labeling immediately and imminently upon approval of ANDA No. 205857.

43. Upon information and belief, Teva will actively induce infringement of the '319 patent when ANDA No. 205857 is approved, and plans and intends to, and will do so immediately and imminently upon approval.

44. Upon information and belief, Teva acted without a reasonable basis for believing that it would not be liable for infringing the '319 patent and/or actively inducing infringement of the '319 patent.

45. Unless Teva is enjoined from infringing the '319 patent and/or actively inducing infringement of the '319 patent, Millennium will suffer irreparable injury. Millennium has no adequate remedy at law.

**PRAYER FOR RELIEF**

WHEREFORE, Millennium prays that this Court grant the following relief:

(a) A judgment that Teva's submission of ANDA No. 205857 was an act of infringement of the '446 and '319 patents, and that Teva's manufacture, use, offer to sell, sale, or importation of the Teva ANDA Product prior to the expiration of the '446 and '319 patents, will infringe and/or actively induce infringement of the '446 and '319 patents;



(b) An Order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any FDA approval of Teva's ANDA No. 205857, or any product or compound that infringes the '446 and '319 patents, shall not be earlier than the expiration of the '446 and '319 patents;

(c) An Order permanently enjoining Teva, and its affiliates and subsidiaries, and each of their officers, agents, servants and employees, from making, have made, using, offering to sell, selling, marketing, distributing, or importing the Teva ANDA Product, or any product or compound that infringes the '446 and '319 patents, or inducing the infringement of the '446 and '319 patents until after the expiration of the '446 and '319 patents;

(d) A declaration that this is an exceptional case and an award of attorneys' fees to Millennium pursuant to 35 U.S.C. §§ 285 and 271(e)(4), together with its reasonable costs; and

(e) Such further and other relief as this Court deems proper and just.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP



Jack B. Blumenfeld (#1014)  
Maryellen Noreika (#3208)  
1201 North Market Street  
P.O. Box 1347  
Wilmington, DE 19899  
(302) 658-9200  
jblumenfeld@mnat.com  
mnoreika@mnat.com

*Attorneys for Plaintiff*

OF COUNSEL:

William F. Lee  
Lisa J. Pirozzolo  
Emily R. Whelan  
Jason H. Liss  
WILMER CUTLER PICKERING  
HALE AND DORR LLP  
60 State Street  
Boston, MA 02109  
(617) 526-6000

Robert M. Galvin  
Russell Tonkovich  
WILMER CUTLER PICKERING  
HALE AND DORR LLP  
950 Page Mill Road  
Palo Alto, CA 94304  
(650) 858-6000

January 22, 2014